Jpmorgan Chase & CO Ab Cellera Biologics Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 334,264 shares of ABCL stock, worth $966,022. This represents 0.0% of its overall portfolio holdings.

Number of Shares

334,264

Previous 370,765 9.84%

Holding current value

$966,022

Previous $1.68 Million 41.1%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$2.73 - $4.73 $99,647 - $172,649	-36,501 Reduced 9.84%	334,264 $989,000
Q1 2024 May 10, 2024	SELL	$4.29 - $5.97 $165,139 - $229,809	-38,494 Reduced 9.41%	370,765 $1.68 Million
Q4 2023 Feb 12, 2024	SELL	$3.91 - $5.93 $496,706 - $753,317	-127,035 Reduced 23.69%	409,259 $2.34 Million
Q3 2023 Nov 14, 2023	BUY	$4.6 - $7.95 $283,189 - $489,425	61,563 Added 12.97%	536,294 $2.47 Million
Q2 2023 Aug 11, 2023	SELL	$5.66 - $7.59 $1.34 Million - $1.8 Million	-236,555 Reduced 33.26%	474,731 $3.07 Million
Q1 2023 May 18, 2023	BUY	$7.31 - $11.18 $1.91 Million - $2.92 Million	260,934 Added 57.94%	711,286 $5.36 Million
Q1 2023 May 11, 2023	SELL	$7.31 - $11.18 $1.04 Million - $1.6 Million	-142,832 Reduced 24.08%	450,352 $3.4 Million
Q4 2022 Feb 13, 2023	BUY	$9.48 - $14.52 $882,151 - $1.35 Million	93,054 Added 18.61%	593,184 $6.01 Million
Q3 2022 Nov 14, 2022	BUY	$9.2 - $13.68 $828,239 - $1.23 Million	90,026 Added 21.95%	500,130 $4.95 Million
Q2 2022 Aug 11, 2022	BUY	$5.72 - $10.65 $1.48 Million - $2.76 Million	259,222 Added 171.8%	410,104 $4.37 Million
Q1 2022 May 11, 2022	BUY	$7.46 - $14.14 $513,576 - $973,454	68,844 Added 83.92%	150,882 $1.47 Million
Q4 2021 Feb 10, 2022	BUY	$12.99 - $17.73 $1.07 Million - $1.45 Million	82,038 New	82,038 $1.17 Million

Others Institutions Holding ABCL

# of Institutions

171

Shares Held

119M

Call Options Held

239K

Put Options Held

200K

View Full List

About AbCellera Biologics Inc.

Ticker ABCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 285,139,008
Market Cap $824M
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...

More about ABCL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Ab Cellera Biologics Inc. Transaction History